| Name | Doxycycline hydrochloride |
| Description | Doxycycline hydrochloride (Hyclate) is a synthetic tetracycline derivative with similar antimicrobial activity. |
| Cell Research | Doxycycline is diluted in culture medium at a concentration of 10 μg/mL. All in vitro treatments are performed in SMC cultures at 90% confluence, when ECM synthesis in SMC starts to be evident. Doxycycline (20 nM) is diluted in culture medium at a concentration of 10 μg/mL (20 nM), at which no toxicity or variation in primary cultured SMC proliferation has been reported, as well as in other cell lines and the incubation time is 48 h. SMC-C and SMC-Ch are seeded at equal cell density in 6-well plates and, when confluence reaches 90%, 1 mL culture medium is added to each well containing 3.7×104?Bq L-[5-H3]-proline (9.62×1011 Bq/mmol). After 48?h incubation, cells are lysed with 0.5 mL 0.5 mol/L NaOH for 1 h. The resulting solution is neutralized with an equal amount of 0.5 mol/L HCl, and 50 μL are used to measure total proteins with the Bradford method. One volume of 10% TCA is added to the remaining 250 μL and centrifuged at 13,000 g for 15?min at 4°C. The resulting precipitate is dissolved in 100 μL 0.2 mol/L NaOH, and then neutralized with 1 mol/L HCl. The solution is incubated with collagenase buffer (Tris-HCl, pH 7.6 20 mM, and CaCl2 250 mM final concentration) and 10 units of collagenase at 37°C overnight. Then, 150 μL 10% TCA are added and centrifuged at 13000 g for 15?min at 4°C. The resulting supernatant is added to 4 mL of scintillation fluid and the radioactivity is measured in a liquid scintillation counter LS 600 TA. |
| Kinase Assay | Gelatin (0.1% (w/v) is added to standard LaemmLi acrylamide polymerization mixture. Tissue extract is mixed 1:2 with sample buffer [250 mM Tris-Cl pH 6.8, 10% (w/v) SDS, 20% (v/v) glycerol, 0.005% (w/v) bromphenol blue]. Serum is diluted 1:10 with electrophoresis buffer (2.5 mM Tris, 20 mM glycine, 0.005% SDS) and mixed 1:2 with sample buffer. Twenty μLs are loaded after 10-min incubation at room temperature without boiling. After electrophoresis at 90 V, the gels are soaked in 2.5% (w/v) Triton X-100, incubated 2 to 3 days at 37°C in gelatin digestion buffer [50 mM Tris-Cl, pH 8.0, 8 mM CaCl2, 10 mM ZnSO2, 0.02% (w/v) NaN3], stained in 0.05% Coomassie blue R-250 in acetic acid/methanol/water (1:4.5:4.5 by volume), destained in 10% acetic acid and 5% methanol, and scanned for lysis band intensity. The lysis band intensity is proportional to gelatinase activity and is quantified densitometrically by using One-Dimensional Scan software. The result, a number between 0.07 and 3.75, is normalized to the protein content by dividing the densitometry result with the relative optical density from the BCA protein assay kit result. The result is used for the analysis as the arbitrary unit. For the total MMP activity results of lysis bands of pro-MMP-9, active MMP-9, pro-MMP-2, and active MMP-2 are added. A protein size marker is used to determine the correct size. |
| In vitro | In Wistar rats, daily administration of Doxycycline (25 mg) effectively inhibits the structural degradation of aortic elastin, diminishes the activity of matrix metalloproteinases MMP-2 and MMP-9 in the arterial wall, and consequently reduces the replication of smooth muscle cells in the intima. |
| In vivo | Doxycycline (50 μM) downregulates the expression of MMP-8 at both mRNA and protein levels in rheumatoid synovial fibroblasts and endothelial cells while completely inhibiting the degradation of type II collagen. Additionally, in corneal epithelial cells, doxycycline suppresses the increase in mRNA and protein levels of IL-1β induced by lipopolysaccharide. |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 10 mM
|
| Keywords | Inhibitor | Matrix metalloproteinases | LNT-229 | G55 | inhibit | Doxycycline hydrochloride | Antibiotic | 293T | U343 | MMP | Doxycycline | anti-proliferative activity | Doxycycline Hydrochloride | MCF 12A | Bacterial | antibacterial activity | SVG |
| Inhibitors Related | Neomycin sulfate | Dimethyl sulfoxide |
| Related Compound Libraries | Anti-Cancer Clinical Compound Library | Anti-Bacterial Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
